Targeting neuroblastoma cancer cells: A screening workflow for antibody-drug conjugates

In this SelectScience webinar, Dr. Rachel Forfar, Senior Scientist at LifeArc, will describe the development of a screening platform for antibody-drug conjugates targeting neuroblastoma cancer cells.

Over expression of mutated anaplastic lymphoma kinase (ALK) has been linked to neuroblastoma cancer cells and is associated with poor prognosis in young patients. This webinar covers a novel approach whereby cytotoxic agents are conjugated to ALK-specific antibodies as a mechanism of directly targeting ALK-expressing neuroblastoma cells and the development of a suitable screening platform.

Join the webinar to learn about:

• LifeArc cell-based assays that utilize advanced flow cytometry and live-cell analysis
• An assessment of cell cytotoxicity using secondary antibodies conjugated to potent toxins
• The challenges of screening, from initial stages with hybridoma supernatants, through to candidate antibodies and towards effectively identifying antibodies with the desired properties of an antibody-drug conjugate (ADC)